Pharvaris (PHVS) has released an update.
Pharvaris, a biopharmaceutical company focusing on oral treatments for hereditary angioedema (HAE), has scheduled its annual shareholder meeting for June 28, 2024. The meeting details and documentation will be accessible on the company’s website in the ‘Investors’ section, as well as on the SEC’s website. Interested shareholders are invited to register for the event following the instructions provided in the meeting notice.
For further insights into PHVS stock, check out TipRanks’ Stock Analysis page.
